N Concordance 1 acarbazine (BOLD) with intercycle alpha interferon-2b in previously untreated pa 2 antiproliferative effects. Recombinant interferon a is approved for use in the 3 eflect liver histology accurately after interferon alfa treatment and may undere 4 these trials are available, high-dose interferon alfa should be considered 5 quantitative measurement of recombinant interferon alfa-2b (IFN alfa-2b) in seru 6 is predictive for response to high-dose interferon-alpha 2b treatment for chroni 7 ve to the lower dosage. Human leucocyte interferon-alpha therapy significantly i 8 ined the effect of local treatment with interferon-alpha on MHC Class I and II e 9 patients treated with recombinant human interferon-beta 1a from mammalian cells. 10 is with sodium stibogluconate and gamma interferon depends on continued interleu 11 lecules comparable to levels induced by interferon-gamma (IFN-gamma) treatment. 12 s of a novel chain of the murine type I interferon (IFN) receptor and characteri 13 certain types of late stage cancer have interferon inhibitory activity in their 14 covery of a more general involvement of interferon regulatory factors in mediati 15 esponse is very low and interruption of interferon therapy may be considered.